<DOC>
	<DOCNO>NCT02679378</DOCNO>
	<brief_summary>Prospective , single-arm , multicenter , open label , non-randomized exploratory clinical study compare ClearSight system histopathological determine negative-margins breast conserve surgery .</brief_summary>
	<brief_title>Exploratory Study Comparing ClearSight System 2D Map Post Surgery Histopathological Analysis Lumpectomy</brief_title>
	<detailed_description>This study multicenter , non-randomized , cross-sectional comparative exploratory study compare ClearSight System 2D map result post surgery histopathological analysis excise mass lumpectomy surgery . The Efficacy Objective ass ability ClearSight™ System detect malignant tissue less equal 1 mm margin excise breast specimen breast conserve surgery use histopathological assessment reference . The Safety Objective adverse event , serious adverse event ( SAE ) report accord local regulation . The actual reporting discuss section 0 . No device-related adverse event expect . For information please refer Investigator Brochure .</detailed_description>
	<criteria>1 . Women histologically diagnose carcinoma breast , schedule primary lumpectomy ( partial mastectomy ) procedure . 2 . Age ≥18 . 3 . Signed ICF 1 . Prior surgical procedure breast within 12 month prior surgery date . 2 . Recurrent breast cancer surgery . 3 . Neoadjuvant chemotherapy . 4 . Previous radiation therapy operate breast . 5 . Pregnant / breast feeding . 6 . Participating study might affect result .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>